Abstract
Primary gastric non-Hodgkin’s lymphomas (PG-NHL) are the most common extranodal lymphomas, representing between 47% and 74% of all gastrointestinal lymphoma cases. In Western countries two histological types, diffuse large B-cell (DLBC) NHL and mucosa-associated lymphoid tissue (MALT) NHL, are more frequently represented, accounting for the majority of gastric tumors after adenocarcinoma. For several years treatment of these PG lymphomas consisted of surgery, chemotherapy and radiotherapy, alone or in combination. In the last two decades however, advances in our understanding of their pathogenesis and biology have changed the treatment strategy, at least as regards the early stages of disease. In addition to making tumor regression possible through the eradication of Helicobacter pylori, which is considered the main pathogenic agent, this understanding has also provided a solid rationale to assess the efficacy of targeted therapy, namely of drugs which interfere with specific molecules expressed by tumor cells or are involved in key growth pathways of these lymphomas. In particular, rituximab, a monoclonal anti-CD20 antibody, radioimmunotherapy, the first-generation proteasome inhibitor bortezomib and lenalidomide have been evaluated. Despite significant antitumor activity in this subset of NHL and manageable toxicity, many questions still remain however about the optimal dose, the best administration schedule and their combination with conventional chemotherapy. This review focuses on the pathogenesis of PG-MALT and DLBC lymphomas, and discusses the results of clinical trials on the impact of new agents on prognosis and survival in these patients, considering also potential new therapautic targets.
Keywords: Bortezomib, diffuse large B-cell lymphoma, eradication therapy, Helicobacter pylori, MALT lymphoma, pathogenesis, stomach, rituximab, targeted therapies, 90Y-Ibritumomab tiuxetan.
Current Medicinal Chemistry
Title:Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs
Volume: 21 Issue: 8
Author(s): Francesca Merchionne, Pasquale Iacopino, Carla Minoia, Angela Iacobazzi, Antonio Rana, Simona Serrati, Giacoma De Tullio, Giacomo Loseto, Angela Lapietra, Annunziata Lucarelli and Attilio Guarini
Affiliation:
Keywords: Bortezomib, diffuse large B-cell lymphoma, eradication therapy, Helicobacter pylori, MALT lymphoma, pathogenesis, stomach, rituximab, targeted therapies, 90Y-Ibritumomab tiuxetan.
Abstract: Primary gastric non-Hodgkin’s lymphomas (PG-NHL) are the most common extranodal lymphomas, representing between 47% and 74% of all gastrointestinal lymphoma cases. In Western countries two histological types, diffuse large B-cell (DLBC) NHL and mucosa-associated lymphoid tissue (MALT) NHL, are more frequently represented, accounting for the majority of gastric tumors after adenocarcinoma. For several years treatment of these PG lymphomas consisted of surgery, chemotherapy and radiotherapy, alone or in combination. In the last two decades however, advances in our understanding of their pathogenesis and biology have changed the treatment strategy, at least as regards the early stages of disease. In addition to making tumor regression possible through the eradication of Helicobacter pylori, which is considered the main pathogenic agent, this understanding has also provided a solid rationale to assess the efficacy of targeted therapy, namely of drugs which interfere with specific molecules expressed by tumor cells or are involved in key growth pathways of these lymphomas. In particular, rituximab, a monoclonal anti-CD20 antibody, radioimmunotherapy, the first-generation proteasome inhibitor bortezomib and lenalidomide have been evaluated. Despite significant antitumor activity in this subset of NHL and manageable toxicity, many questions still remain however about the optimal dose, the best administration schedule and their combination with conventional chemotherapy. This review focuses on the pathogenesis of PG-MALT and DLBC lymphomas, and discusses the results of clinical trials on the impact of new agents on prognosis and survival in these patients, considering also potential new therapautic targets.
Export Options
About this article
Cite this article as:
Merchionne Francesca, Iacopino Pasquale, Minoia Carla, Iacobazzi Angela, Rana Antonio, Serrati Simona, Tullio De Giacoma, Loseto Giacomo, Lapietra Angela, Lucarelli Annunziata and Guarini Attilio, Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs, Current Medicinal Chemistry 2014; 21 (8) . https://dx.doi.org/10.2174/09298673113209990235
DOI https://dx.doi.org/10.2174/09298673113209990235 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal
Current Signal Transduction Therapy Synthesis of [<sup>64</sup>Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Current Radiopharmaceuticals Synthetic Peptides As Non-Viral DNA Vectors
Current Gene Therapy Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells
Current Gene Therapy Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: The Lung and Winding Road: Twists and Turns on the Way to Personalized NSCLC Therapy)
Current Pharmaceutical Design Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Current Pharmaceutical Design Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico
Current Drug Targets Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry